Hagemeijer A
Baillieres Clin Haematol. 1987 Dec;1(4):963-81. doi: 10.1016/s0950-3536(87)80034-3.
The Ph chromosome is the hallmark of CML, where it is found in more than 90% of the cases. Cytogenetically, it usually results from a t(9;22)(q34;q11). The Ph arises in a stem cell and in chronic phase is found in all haematopoietic cell lineages, although it causes only increased granulopoiesis, and sometimes increased thrombopoiesis; furthermore blast crisis may occur in all differentiative patterns of the pluripotent stem cell. Recently, molecular investigations of Ph positive CML cases have revealed a consistent genomic recombination between two genes, BCR on chromosome 22 and the ABL oncogene. The latter is translocated from 9q34, its normal site, to the 22q- or Ph chromosome. This molecular rearrangement expresses a unique 8.5 kb BCR-ABL hybrid mRNA transcript, that encodes an altered BCR-ABL protein of approximately 210 kD with enhanced in vitro tyrosine kinase activity. The breakpoints on chromosome 22q- are clustered in a 5 kb DNA fragment, allowing their study using Southern blot analysis. Cytogenetic variant forms of the Ph translocation involving three or more chromosomes are found in about 5% of the cases. Southern blot and in situ hybridization studies have demonstrated that these variants are cytogenetically more complex than the standard t(9;22) but molecularly they show the same essential genomic recombination. This is also true for a small number of cases of Ph negative CML. Clonal progression, indicated by the presence of clonal, non-random chromosome abnormalities, in addition to the Ph is rare during chronic phase but is found in 80% of blast crisis. These additional aberrations may precede BC by weeks or months and have therefore a clear prognostic value. Ph is not restricted to CML, since it is also found in ALL (20% of adult cases) and rarely in AML. Ph in acute leukaemia is cytogenetically indistinguishable from Ph in CML, but molecular studies have shown that in 50% of the cases the breakpoint on chromosome 22 is different from the very consistent and characteristic breakpoint in CML. Nevertheless genomic recombination takes place that results in a novel ABL protein at least in some of the cases. Despite extensive cytogenetic and molecular investigations, the mechanisms underlying the formation of the Ph as well as the pathogenesis of Ph positive CML are still unknown but are now the object of intensive research.
费城染色体(Ph染色体)是慢性粒细胞白血病(CML)的标志,在超过90%的病例中可检测到。细胞遗传学上,它通常源于t(9;22)(q34;q11)。Ph染色体出现在干细胞中,在慢性期存在于所有造血细胞谱系中,尽管它仅导致粒细胞生成增加,有时也会导致血小板生成增加;此外,多能干细胞的所有分化模式都可能发生急变期。最近,对Ph阳性CML病例的分子研究发现,22号染色体上的BCR基因与ABL癌基因之间存在一致的基因组重组。后者从其正常位点9q34易位至22q-或Ph染色体。这种分子重排表达一种独特的8.5 kb BCR-ABL杂交mRNA转录本,其编码一种改变后的约210 kD的BCR-ABL蛋白,具有增强的体外酪氨酸激酶活性。22q-染色体上的断点聚集在一个5 kb的DNA片段中,可通过Southern印迹分析进行研究。约5%的病例中发现涉及三条或更多条染色体的Ph易位的细胞遗传学变异形式。Southern印迹和原位杂交研究表明,这些变异在细胞遗传学上比标准t(9;22)更复杂,但在分子水平上它们显示出相同的基本基因组重组。少数Ph阴性CML病例也是如此。除Ph染色体外,慢性期很少出现由克隆性、非随机染色体异常所提示的克隆进展,但在80%的急变期病例中可发现。这些额外的畸变可能在急变期前数周或数月出现,因此具有明确的预后价值。Ph染色体并不局限于CML,因为它也见于急性淋巴细胞白血病(ALL,20%的成人病例),很少见于急性髓系白血病(AML)。急性白血病中的Ph染色体在细胞遗传学上与CML中的Ph染色体无法区分,但分子研究表明,50%的病例中22号染色体上的断点与CML中非常一致且具有特征性的断点不同。然而,至少在一些病例中仍会发生基因组重组,从而产生一种新的ABL蛋白。尽管进行了广泛的细胞遗传学和分子研究,但Ph染色体形成的机制以及Ph阳性CML的发病机制仍然未知,但目前是深入研究的对象。